28 February 2025
Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.
Investors
We’re dsm-firmenich – innovators in nutrition, health, and beauty
dsm-firmenich at a glance
Two global leaders in science and innovation, each with a world-class portfolio, have come together to create dsm-firmenich. Our roots may go back well over a century, but we’re always looking forward.
Financial calendar
March 25, 2025
ESG Expert Investor Event - Kaiseraugst
April 30, 2025
Q1 2025 trading update
May 6, 2025
Annual General Shareholders Meeting
Purpose-driven performance
dsm-firmenich brings together two iconic companies. We have deep roots and a bright future, with shared strengths and unrivaled expertise that drive positive impact in everything we do. Our purpose is to bring progress to life – creating a world of potential for customers, communities, consumers, and investors.
dsm-firmenich reports Full Year 2024 results
dsm-firmenich announced its full year 2024 results on February 13, 2025.
Contact Investor relations
EMTN Program Documents
Discover and read about our EMTN Program related documents.
Latest news
-
-
19 February 2025
dsm-firmenich issues €750 million long-term bond
-
13 February 2025
dsm-firmenich reports full year 2024 results
-
11 February 2025
dsm-firmenich to sell stake in Feed Enzymes Alliance to its partner Novonesis for €1.5 billion
-
21 November 2024
DSM-Firmenich AG sold all of its stake in Robertet S.A.
-
15 November 2024
DSM-Firmenich AG sold the majority of its stake in Robertet S.A.
-
14 November 2024
DSM-Firmenich AG to sell part of its stake in Robertet S.A.
-
31 October 2024
dsm-firmenich Q3 2024 trading update
-
24 October 2024
dsm-firmenich receives validation from the Science Based Targets initiative for its 2045 net-zero targets
-
2 October 2024
dsm-firmenich completes the sale of yeast extract business to Lesaffre
-
1 October 2024
dsm-firmenich completes the sale of its MEG-3® fish oil business to KD Pharma Group SA
-
8 August 2024
dsm-firmenich concludes new €1.8 billion Revolving Credit Facility
-
30 July 2024
dsm-firmenich reports H1 2024 results
-
18 July 2024
dsm-firmenich to sell MEG-3® fish oil business to KD Pharma Group
-
26 June 2024
dsm-firmenich issues €800 million long-term bond
-
14 June 2024
DSM shareholders can voluntarily transfer their shares to dsm-firmenich before July 2, 2024, 17:45 hours CEST
-
12 June 2024
dsm-firmenich announces sale of yeast extract business to Lesaffre
-
3 June 2024
dsm-firmenich takes strategic actions to strengthen its position as a leading creation and innovation partner in Nutrition, Health and Beauty
-
31 May 2024
dsm-firmenich implements a cross guarantee agreement to mitigate structural subordination and establish a pari-passu debt platform
-
29 May 2024
Methane-reducing feed ingredient Bovaer® ready for US market launch
-
7 May 2024
dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2024
-
7 May 2024
Share repurchase program to cover share plans completed
-
2 May 2024
dsm-firmenich Q1 2024 trading update
-
30 April 2024
dsm-firmenich's progress on share repurchase program to cover share plans
-
16 April 2024
dsm-firmenich completes on-market repurchase of 500,000 shares to cover share plans
-
8 April 2024
dsm-firmenich announces repurchase of 1.5m shares to cover share plans
-
8 March 2024
dsm-firmenich completes the divestiture of its Jiangshan Vitamin C plant in China
-
29 February 2024
dsm-firmenich publishes 2023 Integrated Annual Report
-
15 February 2024
dsm-firmenich reports 2023 full year results
-
14 February 2024
dsm-firmenich to separate out Animal Nutrition & Health business from the Group
-
12 February 2024
dsm-firmenich completes voluntary cash offer for DSM shares
-
8 January 2024
dsm-firmenich makes voluntary cash offer for DSM shares
-
31 October 2023
dsm-firmenich reports Q3 2023 results
-
10 October 2023
dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition
-
4 October 2023
dsm-firmenich provides additional pro forma financial information for 2022 and 2023
-
2 August 2023
dsm-firmenich reports H1 2023 results
-
3 July 2023
dsm-firmenich completes acquisition of postbiotics pioneer Adare Biome
-
29 June 2023
dsm-firmenich announces results of extraordinary general meeting of shareholders
-
28 June 2023
Trading update and acceleration of strategic actions
-
22 May 2023
Emmanuel Butstraen appointed as President of Perfumery & Beauty at dsm-firmenich
-
17 May 2023
dsm-firmenich names Katharina Stenholm as Chief Sustainability Officer
-
9 May 2023
dsm-firmenich launches as innovators in nutrition, health, and beauty
-
9 May 2023
Completion of contribution of Firmenich shares
-
4 May 2023
dsm-firmenich announces evolution of CEO structure per 1 September, following completion of the merger
-
2 May 2023
DSM provides Q1 2023 trading update
-
1 May 2023
Final results of the exchange offer: 96.1% of DSM ordinary shares tendered
-
18 April 2023
dsm-firmenich first day of trading on Euronext Amsterdam
Explore more
-
dsm-firmenich at a glance
Who we are. Why we merged. Where we’re going.
-
Share center
All the key details on holding and trading shares of dsm-firmenich.